These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
478 related articles for article (PubMed ID: 25494812)
1. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. Marchetti C; De Felice F; Palaia I; Perniola G; Musella A; Musio D; Muzii L; Tombolini V; Panici PB BMC Womens Health; 2014 Dec; 14():150. PubMed ID: 25494812 [TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Rebbeck TR; Kauff ND; Domchek SM J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781 [TBL] [Abstract][Full Text] [Related]
3. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246 [TBL] [Abstract][Full Text] [Related]
4. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832 [TBL] [Abstract][Full Text] [Related]
5. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356 [TBL] [Abstract][Full Text] [Related]
6. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157 [TBL] [Abstract][Full Text] [Related]
7. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
8. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis. Wang Y; Song Z; Zhang S; Wang X; Li P Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860 [TBL] [Abstract][Full Text] [Related]
9. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257 [TBL] [Abstract][Full Text] [Related]
10. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752 [TBL] [Abstract][Full Text] [Related]
12. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974 [TBL] [Abstract][Full Text] [Related]
13. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374 [TBL] [Abstract][Full Text] [Related]
14. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. Garcia C; Lyon L; Conell C; Littell RD; Powell CB Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567 [TBL] [Abstract][Full Text] [Related]
15. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252 [TBL] [Abstract][Full Text] [Related]
16. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397 [TBL] [Abstract][Full Text] [Related]
17. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426 [TBL] [Abstract][Full Text] [Related]
20. Risk management options elected by women after testing positive for a BRCA mutation. Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]